Correspondence 0001437749-23-025385 from NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) (CIK 0000810509)
Date: Sept. 7, 2023 · CIK: 0000810509 · Accession: 0001437749-23-025385
AI Filing Summary & Sentiment
File numbers found in text: 333-274246
Letter
navb20230907_corresp.htm
September 7, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jason Drory, Attorney
Re:
Navidea Biopharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-274246
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274246) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on September 8, 2023, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Bill Mower of Maslon LLP, counsel to the registrant, at (612) 672-8358.
Very truly yours,
NAVIDEA BIOPHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm navb20230907_corresp.htm September 7, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Jason Drory, Attorney Re: Navidea Biopharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-274246 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-274246) (the “Registration Statement”) to become effective at 4:30 p.m. Eastern Time on September 8, 2023, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Bill Mower of Maslon LLP, counsel to the registrant, at (612) 672-8358. Very truly yours, NAVIDEA BIOPHARMACEUTICALS, INC. By: /s/ Craig Dais Craig Dais. Chief Financial Officer cc: William M. Mower, Maslon LLP